Halazepam: Difference between revisions
No edit summary |
No edit summary |
||
Line 50: | Line 50: | ||
| synonyms = <small>9-chloro- 6-phenyl- 2-(2,2,2-trifluoroethyl)- 2,5-diazabicyclo[5.4.0] undeca- 5,8,10,12-tetraen -3-one</small> | | synonyms = <small>9-chloro- 6-phenyl- 2-(2,2,2-trifluoroethyl)- 2,5-diazabicyclo[5.4.0] undeca- 5,8,10,12-tetraen -3-one</small> | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Halazepam''' is a [[benzodiazepine]] derivative that was marketed under the brand names '''Paxipam''' in the United States,<ref name=DrugsH /> '''Alapryl''' in Spain,<ref name=DrugsA>{{cite web|title=Alapryl|url=http://www.drugs.com/international/alapryl.html|publisher=Drugs.com|accessdate=December 11, 2014}}</ref> and '''Pacinone''' in Portugal.<ref name=DrugsP>{{cite web|title=Pacinone|url=http://www.drugs.com/international/pacinone.html|publisher=Drugs.com|accessdate=December 11, 2014}}</ref> | '''Halazepam''' is a [[benzodiazepine]] derivative that was marketed under the brand names '''Paxipam''' in the United States,<ref name=DrugsH /> '''Alapryl''' in Spain,<ref name=DrugsA>{{cite web|title=Alapryl|url=http://www.drugs.com/international/alapryl.html|publisher=Drugs.com|accessdate=December 11, 2014}}</ref> and '''Pacinone''' in Portugal.<ref name=DrugsP>{{cite web|title=Pacinone|url=http://www.drugs.com/international/pacinone.html|publisher=Drugs.com|accessdate=December 11, 2014}}</ref> | ||
Latest revision as of 14:24, 13 April 2015
Clinical data | |
---|---|
Synonyms | 9-chloro- 6-phenyl- 2-(2,2,2-trifluoroethyl)- 2,5-diazabicyclo[5.4.0] undeca- 5,8,10,12-tetraen -3-one |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a684001 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Hepatic |
Elimination half-life | 14 hours (drug), 50-100 hours (metabolites). |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C17H12ClF3N2O |
Molar mass | 352.7 |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Halazepam |
Articles |
---|
Most recent articles on Halazepam |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Halazepam at Clinical Trials.gov Clinical Trials on Halazepam at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Halazepam
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Halazepam Discussion groups on Halazepam Directions to Hospitals Treating Halazepam Risk calculators and risk factors for Halazepam
|
Healthcare Provider Resources |
Causes & Risk Factors for Halazepam |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,[1] Alapryl in Spain,[2] and Pacinone in Portugal.[3]
Medical uses
Halazepam was used for the treatment of anxiety.[1]
Adverse effects
Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.[1]
Pharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published in June 15, 1998 as follows:[4]
Onset of action | Intermediate to slow |
Plasma half life | 14 hr for parent drug and 30-100 hr for its metabolite |
Peak plasma levels | 1-3 hr for parent drug and 3-6 hf for its metabolite |
Metabolism | Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver) |
Excretion | Excreted through kidneys |
Protein binding | 98% bound to plasma protein |
Regulatory Information
Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).[5]
Commercial production
Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "halazepam". Drugs.com. Retrieved December 11, 2014.
- ↑ "Alapryl". Drugs.com. Retrieved December 11, 2014.
- ↑ "Pacinone". Drugs.com. Retrieved December 11, 2014.
- ↑ Quitkin, Frederick M. ... (1998). Current therapeutic drugs (2nd ed. ed.). Washington: American Psychiatric Press. p. 166. ISBN 0880489944.
- ↑ "SCHEDULES OF CONTROLLED SUBSTANCES". Code of Federal Reguations. 2012-04-01. pp. § 1308.14 Schedule IV. Retrieved December 12, 2014.
- Pages with script errors
- CS1 maint: Extra text
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drugboxes which contain changes to watched fields
- Benzodiazepines
- Organochlorides
- Organofluorides
- Lactams
- Drug